Citigroup and Leerink are the bookrunners; JMP and Oppenheimer assist
By Devika Patel
Knoxville, Tenn., Nov. 5 – Kura Oncology, Inc. said it priced a $50 million public sale of stock with a $7.5 million greenshoe on Wednesday. The offering was announced Oct. 20.
The company will sell 6.25 million common shares at $8.00 per share. The price per share is identical to the Nov. 4 closing share price.
Citigroup and Leerink Partners are the bookrunning managers.
Settlement is expected Nov. 10.
Proceeds will be used for clinical trials, research and preclinical development and general corporate purposes, including general and administrative expenses, capital expenditures, working capital and prosecution and maintenance of intellectual property.
The biopharmaceutical company is based in La Jolla, Calif.
| Issuer: | Kura Oncology, Inc.
|
| Issue: | Common stock
|
| Amount: | $50 million
|
| Greenshoe: | $7.5 million, or 937,500 shares
|
| Shares: | 6.25 million
|
| Price: | $8.00
|
| Warrants: | No
|
| Bookrunners: | Citigroup and Leerink Partners
|
| Co-lead managers: | JMP Securities and Oppenheimer & Co.
|
| Announcement date: | Oct. 20
|
| Pricing date: | Nov. 4
|
| Settlement date: | Nov. 10
|
| Stock symbol: | Nasdaq: KURA
|
| Stock price: | $8.00 at close Nov. 4
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
